# A Study of Adalimumab on Inflammatory Mediators Following a Systemic Endotoxin Challenge

> **NCT05884242** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 20 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Adalimumab
- **DRUG:** Lipopolysaccharide (LPS)

## Key facts

- **NCT ID:** NCT05884242
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-05-22
- **Primary completion:** 2023-08-01
- **Final completion:** 2023-08-07
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2025-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05884242

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05884242, "A Study of Adalimumab on Inflammatory Mediators Following a Systemic Endotoxin Challenge". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05884242. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*